Bristol Myers Squibb is teaming up with Prothena in a high-stakes lab dance to tackle Alzheimer’s disease with two ...

Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Chardan slashed the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) on May 27, lowering it to $18 from $40 ...

Prothena (PRTA – Research Report) received a Hold rating and price target from Oppenheimer analyst Jay Olson yesterday. The company’s shares closed last Friday at $6.58. Confi ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Prothena (PRTA – Research Report) and Bristol-Myers Squibb (BMY – Research Report). Confident ...

Fintel reports that on May 27, 2025, Oppenheimer downgraded their outlook for Prothena (NasdaqGS:PRTA) from Outperform to Perform. Analyst Price Forecast Suggests 1,057.57% Upside As of May 7, 2025, ...

On Tuesday, Piper Sandler adjusted its outlook on Prothena Corporation (NASDAQ: PRTA) shares, decreasing the price target from $110.00 to $81.00.Despite this change, the firm maintained an ...

Get The Details Here Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday. AL (amyloid light-chain ...